Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Advanced Solid Tumors 357Unspecified Adult Solid Tumor, Protocol Specific 302Advanced Solid Tumor 274Solid Tumor 237Solid Tumors 233Mesothelioma 84Mesothelioma, Malignant 79Solid Tumor, Adult 65Carcinoma, Non-Small-Cell Lung 57Ovarian Neoplasms 38Melanoma 35Lung Neoplasms 29Advanced or Metastatic Solid Tumors 27Neoplasms 26Carcinoma, Renal Cell 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Pancreatic Neoplasms 25Solid Tumours 24Sarcoma 24Colorectal Neoplasms 24Retinoblastoma 22Esophageal Neoplasms 22Advanced Malignant Solid Tumors 22Unspecified Childhood Solid Tumor, Protocol Specific 21Squamous Cell Carcinoma of Head and Neck 20Breast Neoplasms 20Advanced Solid Tumours 20Triple Negative Breast Neoplasms 19Small Cell Lung Carcinoma 19

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors (Excluding Breast Cancer) × Other solid neoplasm × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡